secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001437749-25-017989
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected
--------------------------------------------------------------------------------

- Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).
- All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu; each received majority vote.
- Ratification of Grant Thornton LLP as auditor for fiscal 2025 approved with 4.12M for, 134k against.
- Non-binding advisory vote on executive compensation passed with 2.39M for, 268k against.
- Quorum of 70% (4.33M shares) present at May 21, 2025 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925017989/0001437749-25-017989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925017989/aytu20250515_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-017989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer